What is Bioprotect?
Founded in 2004 and headquartered in Israel, BioProtect manufactures advanced biodegradable implantable balloon solutions. These devices are designed to safeguard organs at risk during radiation oncology treatments, a critical application in cancer care. Beyond radiation therapy, BioProtect's technology also addresses other unmet needs within surgical procedures, positioning the company as a key innovator in the medical device sector. The company's focus on biodegradable materials highlights a commitment to patient safety and advanced therapeutic delivery systems.
How much funding has Bioprotect raised?
Bioprotect has raised a total of $30.2M across 3 funding rounds:
Series C
$1.7M
Unspecified
$3.5M
Series D
$25M
Series C (2008): $1.7M with participation from Xenia Venture Capital
Unspecified (2017): $3.5M, investors not publicly disclosed
Series D (2020): $25M supported by Accelmed Ventures, Consensus Business Group, Peregrine Ventures, and KB Investments
Key Investors in Bioprotect
Peregrine Ventures
Peregrine Ventures is dedicated to advancing medical innovation through global strategic investments, focusing on life science companies at various stages of development. The company leverages deep industry knowledge and a synergetic strategy to support portfolio companies in bringing groundbreaking healthcare technologies to market.
Consensus Business Group
Consensus Business Group is an investment entity that likely focuses on strategic capital allocation across various sectors, potentially including healthcare and technology, given its participation in Bioprotect's funding round.
Xenia Venture Capital
Xenia Venture Capital is a publicly traded hi-tech investment company on the Tel Aviv Stock Exchange, primarily focused on investing in high tech and med tech sectors in Israel, specializing in life science investments and operating a technological incubator.
What's next for Bioprotect?
With the recent major strategic investment, Bioprotect is poised for accelerated development and market expansion. The substantial capital infusion, reflected in the $30.2M total funding, suggests a company in a scaling phase, likely focusing on enhancing its product pipeline, expanding manufacturing capabilities, and broadening its commercial reach. Future endeavors may include further clinical validation, strategic partnerships, and penetration into new therapeutic areas or geographical markets, solidifying its position in the competitive medtech landscape.
See full Bioprotect company page
